
About Tome Biosciences
Tome Biosciences is a Healthcare company based in Cambridge (United States) founded in 2021. CRISPR-based gene insertion platform for genomic medicines is developed. Tome Biosciences has raised $213 million across 2 funding rounds from investors including Fujifilm, ARE and Bruker. Tome Biosciences has completed 1 acquisition, including Replace Therapeutics. Its chief executive, as recorded, is Mike Lucero. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its competitors include Senti Biosciences, Poseida Therapeutics and ADARx Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Tome Biosciences was founded in 2021 and is headquartered in Cambridge, United States. A gene insertion platform is developed by the company within the biotechnology sector, focusing on genomic medicines. CRISPR technologies are employed to integrate any genetic sequence into any genome. This approach supports the creation of treatments for patients via genomic medicines and advanced cell therapies. Operations center on research and development for therapeutic applications.
- Total Equity Funding$213M (USD)
in 2 rounds
- InvestorsFujifilm
& 7 more
- Investments & Acquisitions
Funding Insights of Tome Biosciences
Tome Biosciences has successfully raised a total of $213M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $213M
- Total Rounds 2
- First Round $213M
(Dec 2023)
- Investors Count 8
All 2 funding rounds of Tome Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | Series A | β | a16z, Arch Venture Partners | β | |
| Dec 2023 | $213M | Series B | β | a16z, Arch Venture Partners | β |
8 investors in total: 8 institutional.
Investors in Tome Biosciences
Tome Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Fujifilm, ARE and Bruker.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital is directed toward healthcare companies by Longwood Fund. | longwoodfund.com | Boston, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Diversified research instrument systems are manufactured and supplied. | 1960 | bruker.com | United States | |
Multiple sectors are invested in by the venture capital firm. | 1934 | fujifilm.com | Minato, Japan | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States |
Investor details for Tome Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tome Biosciences
47 people are tracked at Tome Biosciences (12 in leadership, 35 in team).
| Name | Role | Group |
|---|---|---|
Mike Lucero | CEO | Leadership |
Xiarong Shi | Director | Leadership |
Adrianne Monsef | Senior Director, Program Team Lead | Leadership |
Diane W. | Chief People Officer | Leadership |
Jun Jiang | Senior Director | Leadership |
Jesse Cochrane | Associate Director | Leadership |
Ravindra Amunugama | Associate Director- Cell Therapy | Leadership |
Gabriela Cline | Director, HRBP | Leadership |
Chong Luo | Director, Cell Therapy | Leadership |
Markvic Naniong | Associate Director | Leadership |
Jie Wang | Associate Director | Leadership |
J Michael Sutton | Senior Scientist, Head Of Mass Spec Group | Leadership |
Qiang Wang | Senior Scientist | Team |
Medina Geyer | Senior Research Associate | Team |
Patrick Tavares | Senior Scientist, Cell Therapy | Team |
Saloni Matta | Senior Research Associate | Team |
Sara Ashrafi | Scientist | Team |
Patrick Hanna | Scientist II | Team |
Angela Nan | Scientist I | Team |
Anya Wilczynski | Human Resources Manager | Team |
27 more people are available in the full profile.
Complete people profiles for Tome Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tome Biosciences
Tome Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Replace Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
CRISPR-based genome editing platform is developed for genetic diseases. | 0 | Jan 2024 | β’β’β’β’ |
Complete acquisition details for Tome Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Tome Biosciences
3 dated milestones of Tome Biosciences across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Tome Biosciences is founded.
- Funding First funding round of $213.0M.
- Acquisition Acquires Replace Therapeutics.
Competitors of Tome Biosciences
Tome Biosciences has 3 listed competitors in our database, 3 of them funded. They include Senti Biosciences, Poseida Therapeutics and ADARx Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sentibio.com | 2016 | San Francisco, United States | $158M | Cell-based therapies for cancer treatment are developed. | ||
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| adarx.com | 2019 | San Diego, United States | $352.5M | 44 | Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts |
Detailed competitors of Tome Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Tome Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tome Biosciences
Complete news archive for Tome Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tome Biosciences
Tome Biosciences was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Tome Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Mike Lucero is the CEO of Tome Biosciences, as recorded in our data.
Tome Biosciences is a funded company, having raised a total of $213M across 2 funding rounds to date.
Tome Biosciences was founded in 2021 and is headquartered in Cambridge, United States. A gene insertion platform is developed by the company within the biotechnology sector, focusing on genomic medicines. CRISPR technologies are employed to integrate any genetic sequence into any genome. This approach supports the creation of treatments for patients via genomic medicines and advanced cell therapies. Operations center on research and development for therapeutic applications.
Tome Biosciences's top competitors include Senti Biosciences, Poseida Therapeutics and ADARx Pharmaceuticals.
Tome Biosciences has made 1 acquisition, including Replace Therapeutics.
Tome Biosciences has 8 investors. Key investors include Fujifilm, ARE, Bruker, Arch Venture Partners, and Andreessen Horowitz.
